DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Sheldon-hall syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSheldon-hall syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sheldon-hall syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 1964 report describes persistent hallucinosis following repeated use of hallucinogenic drugs, adding a single case to a small literature of chronic hallucinatory states after such exposure. No treatment is discussed, and the abstract offers no data on recovery or management. This is the only abstract mentioning any drug, and it concerns a complication of substance use, not a therapy for Sheldon-Hall syndrome.
The remaining abstracts concern Freeman-Sheldon syndrome, a related myopathic arthrogryposis, and none evaluate any pharmacological intervention. A 1986 report on two adults with Freeman-Sheldon syndrome found myopathy on electromyography and muscle biopsy, classified as congenital fibre type disproportion, but gives no treatment data. A 2005 case describes successful awake nasotracheal intubation using a fiberoptic bronchoscope in a 6-year-old on two occasions; this is an airway management technique, not a drug. A 2021 case of an infant with blepharophimosis confirmed a heterozygous MYH3 variant, noted difficult intubation complicated by pneumothorax, and planned eyelid surgery to prevent deprivation amblyopia; no drug therapy is mentioned.
Across these abstracts, there is no evidence for any drug treatment for Sheldon-Hall syndrome or its Freeman-Sheldon variant. The only drug-related content is the 1964 warning about hallucinogen-induced persistent hallucinosis, which is irrelevant to the syndrome's congenital myopathy. What is missing is any clinical trial, case series, or even single-patient report testing a pharmacological agent for this condition; the literature is limited to anaesthetic case reports and surgical management. Without such data, no drug can be assessed for efficacy, and the field lacks even preliminary evidence on which to base a repurposing hypothesis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Psychiatry · 1964 · 84 citations
PERSISTENT HALLUCINOSIS FOLLOWING REPEATED ADMINISTRATION OF HALLUCINOGENIC DRUGS
AbstractThe use of hallucinogenic drugs carries a danger which is not sufficiently recognized, namely that of prolonged adverse reactions. Among these reactions is a chronic hallucinatory state or hallucinosis which is occasionally seen after repeated drug administrations. Several characteristic cases have been reported in the literature and a further case is added here.
Journal of Medical Genetics · 1986 · 53 citations · open access
Freeman-Sheldon syndrome: a disorder of congenital myopathic origin?
AbstractFreeman-Sheldon syndrome was diagnosed in an unrelated adult man and woman, with severe abnormalities of the extremities but only slight anomalies of the face. Electromyography and muscle biopsy showed a myopathy which was classified as a congenital disproportion of fibre type and seemed to be the primary cause of the deformities. This allowed classification of the syndrome as a separate type of myopathic arthrogryposis.
Awake nasotracheal intubation using fiberoptic bronchoscope in a pediatric patient with Freeman–Sheldon syndrome
AbstractThe Freeman-Sheldon syndrome is a congenital disease primarily affecting the facial, limb and respiratory muscles that give rise to classical clinical features including typical whistling face and short webbed neck associated with difficult intubation. We present successful awake nasotracheal intubation in a 6-year-old patient with typical clinical features of Freeman-Sheldon syndrome by using fiberoptic bronchoscope on two separate occasions.
A case of blepharophimosis: Freeman Sheldon syndrome
AbstractPurpose Important implications exist for ophthalmologists when considering possible early surgical intervention for potential amblyogenic anatomical abnormalities. The authors discuss the risks and benefits from an ophthalmological perspective of different interventions and review the genetic testing that confirmed the diagnosis.Observations The authors describe the findings and management of an infant with Freeman Sheldon syndrome presenting with blepharophimosis of both eyelids resulting in inability to open both eyes during the first several days of life. Although the mode of inheritance for Freeman Sheldon syndrome (formerly known as Whistling Face Syndrome) is often autosomal dominant, our patient had no known family history of congenital abnormalities or consanguinity. However, genetic testing confirmed a heterozygous variant in MYH3, consistent with autosomal dominant Freeman Sheldon Syndrome. When our patient required gastrostomy (G-tube_placement, we performed an exam under anesthesia (EUA)). As is typical for Freeman Sheldon syndrome patients, intubation was difficult and complicated by pneumothorax. Eye-opening improved slightly after several weeks of life; however, the decision was made to proceed with eyelid surgery to prevent deprivation amblyopia. Surgery is scheduled for a future date. Additionally, the patient had congenital nasolacrimal duct obstruction of the left eye; however, a probing and irrigation failed because of obstruction from the abnormal facial anatomy.Conclusions and Importance Patients with Freeman Sheldon syndrome are at increased risk for complications from anesthesia and surgery. Risks and benefits should be strongly considered and discussed with parent(s)/guardian(s) prior to any surgical intervention. Genetic testing of the MYH3 gene can confirm the diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
